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Plasminogen activators (PA)' are serine proteases that can
convert the zymogen plasminogen into the active proteolytic
enzyme plasmin. Plasmin, which is also a serine protease, can
in turn degrade most proteins. Plasmin plays a role in a
variety of normal and pathological processes, in which tissue
degradation and thrombolysis have been the most extensively
studied, and mobilization ofplasmin by cellular release ofPA
may be a general mechanism for producing localized extra-
cellular proteolysis (1). Recent findings have demonstrated
that PA are secreted from cells in culture as inactive proen-
zymes (2-5). The overall process leading to the formation of
plasmin is thus a cascade reaction that can be influenced by
regulatory factors and leads to a large amplification of the
proteolytic activity.
Two types of PA can be distinguished, based on molecular
weight (M,) and immunological reactivity (6-17), immuno-
histochemical distribution (18, 19), and the amino acid se-
quences of the proteins and the nucleotide sequences of the
corresponding cDNA (20-22). One type, with M, of approx-
imately 70 Kdaltons (tissue-type PA, t-PA), is assumed to
play a role in plasminogen activation leading to thrombolysis
(18, 23-26). Another type, with M, of -50 Kdalton (uroki-
nase-type PA, u-PA), is believed, among other functions, to
play a role in certain normal and pathological processes that
'Abbreviations used in this paper: PA, plasminogen activator; u-PA,
urokinase-type PA; t-PA, tissue-type PA.
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ABSTRACT The invasively growing and metastasizing Lewis lung carcinoma consistently contained
urokinase-type plasminogen activator (u-PA) enzyme activity. When investigated immunocytochem-
ically with antibodies against u-PA, different parts of individual tumors showed a pronounced
heterogeneity in staining intensity. Strong staining was found in areas with invasive growth and
degradation of surrounding normal tissue, while other areas were completely devoid of staining.
Immunoreactivity occurred both with a perinuclear cytoplasmic localization in tumor cells and
associated with apparently extracellular material. SIDS PAGE of tumor extracts, under both reducing
and nonreducing conditions, followed by immunoblotting, showed only one immunocytochemically
stainable band with an electrophoretic mobility corresponding to that of purified proenzyme to
u-PA, while no two-chain u-PA was detected . This indicates that the major part of the activator in
Lewis lung carcinoma is present as one-chain pro-u-PA.
involve tissue degradation, such as implantation of the fertil-
ized egg into the uterus (27, 28), postlactational involution of
mammary glands (29), inflammation (1, 30), and cancer (1,
10, 31-40). We have reported the purification of murine u-
PA (41), the development of rabbit antibodies against the
purified enzyme (13), and the use of these antibodies for an
immunocytochemical mapping ofthe distribution ofu-PA in
the normal mouse (19). We now report their use for the
immunocytochemical detection of u-PA in the invasively-
growing, transplanted Lewislung carcinoma.
MATERIALS AND METHODS
The following materials were obtained from the indicated sources: Lewis lung
carcinoma (as a gift from Mammalian Genetics and Animal Production Sec-
tion, National Cancer Institute, Bethesda, MD, Urokinase (Leo Pharmaceuti-
cals, Ballerup, Denmark); cyanogen-bromide-activated Sepharose (Pharmacia,
Uppsala, Sweden); swine IgG anti-rabbit immunoglobulins and rabbit antipe-
roxidase-peroxidase (Dakopatts, Copenhagen, Denmark); Millipore nitrocellu-
lose paper GSWP 000 10 (Millipore, Molsheim, France). All other materials
were those described previously (2, 3, 10, 13, 16, 19, 41, 42), or of the best
commercially-availablegrade.
Tumors:
￿
Lewis lung carcinoma (43) was stored frozen in liquid nitrogen
or propagated in female C57/B1 mice at the age of 8-10 wk by subcutaneous
inoculation of -0.5-mm fragments (44). After -2 wk, tumors were either
retransplanted or used forexperiments. In the latter case, micewereanesthetized
with diethylether and perfusion-fixedwith cold (4°C) 0.01 M sodium phosphate
buffer, pH 7.4, containing 0.14 M NaCI (PBS), followed by a cold (4°C) 4%
(wt/vol) paraformaldehyde solution in 0.1 M sodium phosphate buffer, pH 7.4,
asdescribed(19). Tissue used forenzyme assay and electroblotting was removed
753from animals perfused with PBS alone. The tumors used in this study were in
their I1-36th transplantation generation.
Tissue Treatments:
￿
Specimens from animals perfused with parafor-
maldehyde were, as described (19), cut into 1-2-mm cubes and postfixed
overnight (typically, 16 h) at 4°C. This was followed by a 24 h rinsing in 0.1 M
sodium phosphate buffer, pH 7.3, containing 20% sucrose. The tissue cubes
were then frozen in melting Freon-22, sectioned at 4-8 um on a cryostat at
-20°C, and mounted on chromealungelatin-coated slides.
Extracts from frozen samples of freshly PBS-perfused tumor tissue were
prepared, as described (35), with 0.1 M Tris/HCI, pH 8.1, containing 0.5%
(wt/vol) Triton X-100, 10 /Al/mg wet tissue weight. The samples were homog-
enized and centrifuged (4,000 g) at 4°C for 10 min.
Antibodies:
￿
Antibodies against highly-purified murine u-PA were pro-
duced by immunization of rabbits, as described (13). The IgG fraction was
purified by sodium sulphate precipitation and DEAE-Sephadex ion exchange
chromatography (45). The IgG was, as described (19), absorbed against a
glutaraldehyde polymer of murine proteins (46). The glutaraldehyde polymer
was prepared from a mixture of(a) conditioned medium from murine sarcoma
virus-transformed plasminogen activator-producing 3T3 cells (3T3/MSV-10),
depleted of plasminogen activator by three passages through a 4-aminobenza-
midine aminododecyl cellulose column (41), (b) conditioned medium from
murine embryonal fibroblasts (l0), and (c) normal mouse serum. All three
parts were further depleted ofu-PA by being passed through a column of rabbit
antimurine u-PA IgG coupled to Sepharose 4B. The glutaraldehyde polymer
was prepared from 30-ml protein solution in 0.2 M sodium acetate buffer, pH
5.0, containing BSA (25 mg/ml), by slowly adding 6 ml of2.5% glutaraldehyde
(wt/vol). The IgG preparations were applied to and eluted from the polymer in
PBS at 4°C (46).
Preimmune and nonimmune IgG were purified and absorbed in the same
way. The purified IgG preparations were screened for their ability to stain spots
ofmurine pro-u-PA and u-PA (3) with an immunocytochemical model system
(47), in which spots of the activator preparations were applied to Whatman
No. l paper.
Affinity purified antimurine u-PA IgG was prepared by chromatography on
a column containing purified murine u-PA coupled to Sepharose, as described
previously ( l9).
Immunocytochemistry: Cryostat sections or paper models were
soaked, as previously described (19), in 0.05 M Tris HCI, pH 7.4, with 0.15 M
NaCl and I % (wt/vol) Triton X-100 (TBS-Triton) for 15 min, exposed to l
(wt/vol) human serum albumin or 10% normal goat serum in TBS-Triton for
30 min at room temperature, briefly rinsed in TBS-Triton and exposed to
varying concentrations ofantibodies purified as described above. Optimal IgG
concentrations for staining were found to be 5 ug/ml (dilution performed in
TBS with 0.25% BSA) using 20 h of incubation at 4°C followed by 2 h of re-
equilibration at room temperature. The site of antigen-antibody reaction was
revealed by the antiperoxidase-peroxidase method ofStemberger, as described
(42, 48). Peroxidase activity was demonstrated by the diaminobenzidine-H202
method (48) and sections were counterstained lightly with haematoxylin.
In some experiments, endogenous peroxidaseactivity of mouse tumor tissue
was quenched by exposure to methanol:H202 prior to immunocytochemical
staining (42). This treatment somewhat compromised, but did not totally
inhibit, immunocytochemical staining, and was therefore not used routinely.
Whenever employed, adjacent sections not exposed to the methanol:H202
reagent were analyzed in parallel.
Controls were those recommended by Sternberger (48) and included (a)
omission ofeither the first, second, or third layer ofantiserum; (b) substitution
ofthe primary antibodies by preimmune or nonimmune IgG(at concentrations
of 5-50 ug/ml), or by control hyperimmune sera (antigastrin serum 4652,
antisomatostatin serum R213/3); (c) absorption of the primary antibodies
againstvarying concentrations(4.2-63 KU/ml), ofhighly-purified murine pro-
u-PA (3, 41). The pro-u-PA used for antibody absorption showed one Coo-
massie Blue stainable band corresponding to M,48 Kdaltons after SDS PAGE
under reducing as well as nonreducing conditions (3) (detection limit for
possible contaminating proteins -5%).
Plasminogen Activator Assay:
￿
The PA content in tissue extracts
was determined by a modification ofthe l25í-labeled fibrin plate assay, in which
catalytic amounts of plasmin were added to allow for the simultaneous deter-
mination of pro-u-PA and u-PA (3). Each assay well contained 0.5 ml of0. l
M Tris HCI, pH 8.1, 0.1% Triton X-100, 0.25% gelatin, 1 ug human glu-
plasminogen and 7 ng human plasmin. In parallel assays, 0.25 ag affinity
purified antimurine a-PA IgG (l3) was added. This completely inhibited the
enzymatic activity of the purified pro-u-PA and u-PA, while it did not inhibit
murine t-PA (13). Pro-u-PA/u-PA in the samples was calculated as that part of
the activity that was inhibited by the antimurine u-PA IgG. In the assay, a
highly-purified murine pro-u-PA standard preparation (3) (0.5-2 U/ml; see
reference 10 for definition of I U murine u-PA) was used for calibration. The
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same preparation was used as an internal standard to check for the possible
inhibition ofthe assay by inhibitors of plasmin and/or PA (3). In some of the
extracts, a strong inhibition of the internal standard was observed under these
conditions. In these cases, the assay was modified, as described (19), so that the
incubation period was 20 h. Under these conditions the inhibition of the
internal pro-u-PA standard was <15% in all cases.
Electrophoresis and Immunoblotting: SDS PAGE was per-
formed in a stacking system using slab gels with a gradient of 6-16% (wt/vol)
polyacrylamide (l0) and a potential difference of60 V, for 16-18 h. In some
cases, samples were reduced immediately before application to the gel, by being
boiled for 2 min in a buffer containing 5% 2-mercaptoethanol. Following SDS
PAGE, proteins were transferred electrophoretically (10 V, 250 mM, 20 h)
from the polyacrylamidegel onto nitrocellulose paper using a modification (19)
of the procedure of Bumette (49) and stained either with 0.5% amido black in
45% methanol, 10% acetic acid or by the peroxidase-antiperoxidase method,
as described (19).
In each gel, the following mixture of marker proteins was electrophoresed
and transferred by electroblotting: rabbit phosphorylase (M, 94 Kdaltons), BSA
(M, 67 Kdaltons), ovalbumin (M, 43 Kdaltons), carbonic anhydrase (M, 30
Kdaltons), soybean trypsin inhibitor (M,20.1 Kdaltons) and a-lactalbumin (M,
14.4 Kdaltons).
RESULTS
Extracts of nine Lewis lung tumors (primary tumors as well
as lung metastases), from different passages during a period
ofmore than one year, were all found to contain PA activity,
as measured by the 125I-fibrin plate method using plasmin-
enriched plasminogen (this allows for the simultaneous deter-
mination of u-PA and its proenzyme pro-u-PA, see reference
3). Extracts from a variety of murine tissues contain both u-
PA and t-PA (19, 41, and unpublished observations). Rabbit
antibodies directed against murine u-PA completely inhibited
its enzyme activity, without inhibiting t-PA (13). Addition of
rabbit antimurine u-PA in the assay, therefore, enabled us to
determine the proportion of enzyme activity due to u-PA.
This was consistently >90% in all tumor extracts assayed, and
the pro-u-PA/u-PA content in the extracts was found to vary
between 2 and 64 U/mg wet weight of tissue (mean 25 U/
mg, SD 21 U/mg). The finding that u-PA consistently consti-
tuted the majority ofthe plasminogen activator activity in the
Lewis lung carcinoma extracts was further substantiated by
results ofzymographywith overlaying ofSDS polyacrylamide
gels on plasminogen-containing agarose gels (50). In most
cases, only PA with an electrophoretic mobility corresponding
to murine u-PA (Mr -48 Kdaltons) was detected (13). Occa-
sionally, a small amount of PA with an electrophoretic mo-
bility corresponding to murine t-PA (M, -75 Kdalton, see
reference 13) also was found (results not shown).
Immunohistochemical Localization of u-PA
Lewis lung carcinomas consistently contained u-PA im-
munoreactivity, as detected with the peroxidase antiperoxi-
dase technique (48). There was a pronounced heterogeneity
in the staining of different parts of individual tumors: some
parts stained strongly and other parts were devoid of immu-
noreactivity (Fig. I a). This was the case for both primary
tumors and lung metastases. Typically, the most intense im-
munoreactivity was observed in areas of the tumors that were
adjacent to the surrounding tissue, and where, from histolog-
ical criteria, the growth appeared to be invasive with an active
degradation of normal tissue, e.g., of muscle tissue, as shown
in Fig. 1 b. Some of the staining apparently represented
extracellular material, while other parts seemed to represent
intracellular material, often with a perinuclear localization
(Fig. 1 c). Without the aid of electron microscopy, it was notFIGURE 1 Distribution of u-PA immunoreactivity in Lewis lung tumor metastasis invading the chest wall . Antiperoxidase-
peroxidase staining with 5 ug/ml of rabbit anti-murine u-PA IgG (a) . Adjacent section stained with the same concentration of the
antibody preabsorbed with 21 KU/ml of a purified u-PA preparation (a') . b, b' as a, a', respectively; c as a . Note in a the
pronounced staining heterogeneity : most staining occurring in the part of the tumor invading the chest wall (arrow) . b is a close
up view of this area . Muscle fiber remnants are seen (arrows) . c is a higher magnification of tumor cells surrounding a muscle
remnant . Most of the stain is located extracellularly or associated with the cell membranes (see text) but in scattered cells
perinuclear staining also occurs (arrows) . Endogeneous peroxidase activity of granulocytes and pseudoperoxidase activity of
erythrocytes is seen in a, a' and b, b' . This activity was quenched if sections were treated with methanol:H 20 2 before
immunocytochemical staining . x 35 (a); x 140 (b); x 350 (c) .
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tivity was located extracellularly, or whether some of the
apparently extracellular material was attached to the cell
membrane .
Staining controls, including the use of up to 50 wg/ml
nonimmune or preimmune IgG and unrelated hyperimmune
sera, were negative, as were experiments in which the various
antibody layers were deleted . Absorption of the anti-u-PA
antibodies with highly-purified pro-u-PA oru-PA completely
abolished the staining reported above (Fig . 1 a', b') . In all
specimens, erythrocytes and granulocytes were the only cell
types displaying significant endogenous peroxidase activity .
Immunoblotting Analysis
To further investigate the character ofthe stained material,
extracts of Lewis lung carcinoma tissue, purified murine pro-
u-PA, and purified murine a-PA were separated by SDS
PAGE under reducing as well as nonreducing conditions, and
the proteins electrophoretically transferred to nitrocellulose
sheets. Immunocytochemical staining of the nitrocellulose
replicas ofthe Lewis lung carcinoma extracts, separated under
nonreducing conditions, showed only one stained band with
an apparent M, of 48 Kdaltons that was identical to that of
purified murine pro-u-PA (Fig. 2) . We have previously dem-
onstrated (3) that the murine pro-u-PA consists of a single
polypeptide chain, while the active form, u-PA, consists of
two polypeptide chains with apparent M, of 29 Kdaltons and
19 Kdaltons, respectively, held together by one or more
disulphide bridges . As shown in Fig. 3, purified pro-u-PA and
u-PA could still be detected immunocytochemically on nitro-
cellulose replicas after electrophoresis under reducing condi-
tions . Pro-u-PA showed one 48-Kdalton band (lane b) and
active u-PA showed a 29-Kdalton band (lane c), but the 19-
Kdalton band was not detected under these conditions .When
the Lewis lung carcinoma extracts were separated by SDS
PAGE under reducing conditions, immunocytochemical
staining of the nitrocellulose replicas showed only one band
with an electrophoretic mobility that was indistinguishable
from that of murine pro-u-PA electrophoresed in parallel (Fig.
3) . These results demonstrate that the major part (>80%) of
the murine urokinase-type activator in Lewis lung carcinoma
is present in the one-chain form and, therefore, presumably
as the inactive proenzyme pro-u-PA .
DISCUSSION
Antibodies developed against a highly purified preparation of
murine u-PA were used for the immunocytochemical stain-
ing . The staining and absorption controls clearly demonstrate
that nonimmunological binding of the purified IgG prepara-
tion to tissue components can be excluded . The absorption
controls were performed with pro-u-PA and u-PA prepara-
tions that were pure, as evaluated by SDSPAGE . This makes
it unlikely that the staining is due to contaminating antibod-
ies . As for the possibility of the staining being due to cross
reaction with an antigen different from pro-u-PA/u-PA pres-
ent in the Lewis lung tumor, this appears less likely because
of the results obtained in the immunoblotting and zymogra-
phy experiments . In these experiments, only one band with
electrophoretic mobility identical to that of pro-u-PA could
be stained on nitrocellulose replicas from SDS polyacrylamide
gels, and zymography with corresponding nonreduced gels
demonstrates enzymatic activity with the same electropho-
retic mobility .
75 6
￿
RAPID COMMUNICATIONS
FIGURE 2
￿
Immunoblotting analysis of murine u-PA after SIDS poly-
acrylamide gel electrophoresis under nonreducing conditions of
Triton X-100 extracts of Lewis lung tumor (1) and purified prepara-
tions of murine pro-u-PA (2) . Tumor tissue was extracted with 0 .1
M Tris HCI, pH 8 .1, containing 0.5% Triton X-100, and 40 gI of
extract containing 110 U u-PA activity was applied to each of four
lanes (a-d) . Highly purified murine pro-u-PA was applied to each
of four other lanes (42 KU to lane a and 105 U to lanes b-d) .
Following SDS PAGE, the proteins were electrophoretically trans-
ferred onto nitrocellulose paper . The paper was cut longitudinally
and the lanes were either stained with amido black (a) or by the
PAP method using antimurine u-PA IgG (5 jag/m) (b), antimurine u-
PA IgG preabsorbed with murine pro-u-PA (21 KU/ml) (c), or
nonimmune IgG (5 Fig/ml) (d) .
The specificity ofthe staining for u-PA is also supported by
other findings . First, all of the Lewis lung tumor studied
contained less u-PA enzyme activity and fewer immunoreac-
tive cells than superficial mucosa of stomach, while both
parameters in the Lewis lung carcinomas varied within the
range previously observed in vas deferens, kidney, lung, and
placenta in the normal mouse (19) . Secondly, the ability of
these antibodies to detect u-PA specifically is supported by a
previous study of the distribution of u-PA immunoreactivity
in the normal mouse, in which we found that, besides u-PA,
none of the protein bands transferred to nitrocellulose repli-
cas, were stained, although blotting experiments were per-
formed on extracts of a variety of tissues. In summary, we
find that these results provide convincing evidence that the
immunoreactivity detected in the Lewis lung carcinoma rep-
resents authentic pro-u-PA/u-PA . It should be noted, how-
ever, that the results only determine the presence of a certain
amount of pro-u-PA or u-PA in cells or extracellular space at
the time of fixation, and do not necessarily reflect the amount
of production of the activator.
As judged from Fig . 1, a considerable part of the activator
seems to be located extracellularly . The localization might be
an artifact resulting from the processing of the tissue, but this
explanation seems unlikely, however, because the intact ani-FIGURE 3
￿
Immunoblotting analysis of murine u-PA after SDS PAGE
under reducing conditions of Triton X-100 extracts (80 A l, 220 U u-
PA) of Lewis lung tumor (a) and purified preparations (220 U per
lane) of murine pro-u-PA (b) and u-PA (c) . Experimental conditions
were as described for lanes b in Fig . 2, except that each sample
was boiled with 5% 2-mercaptoethanol for 2 min immediately
before electrophoresis .
mals were fixed by perfusion with paraformaldehyde before
the specimens were excised and postfixed . The apparently
extracellular location of a part of the activator is similar to
findings in some organs in the normal mouse, e.g ., u-PA
immuncreactivity apparently was located extracellularly
along the basement membrane and the lamina propria in the
small and large intestine (19) .
The heterogeneity in the cellular content of u-PA within
the same tumor, as documented by this study, agrees well
with the heterogeneity with respect to a variety of other
properties, typical for most malignant neoplasms (51, 52)
including Lewis lung carcinoma (53) . The heterogeneity
found in the Lewis lung carcinoma cells is also in agreement
with a similar cellular heterogeneity in u-PA content found
in an immunofluorescence study of cultured human glioblas-
toma cells with monoclonal antibodies against the activator
(54).
PA activity has previously been found both in cultured
Lewis lung carcinoma cells (55) and in extracts of Lewis lung
carcinoma (56) . Numerous reports have dealt with the pres-
ence of PA in cultured cells derived from malignant neo-
plasms of both human and animal origin . A large variation
in PA activity has been observed among different cultures
derived from the same animal tumor strain, e.g ., the B16
melanoma (57, 58), and among cell cultures derived from
tumors of the same histological type from different patients
(59). The present finding of u-PA heterogeneity within indi-
vidual tumors indicates that selection of different tumor cell
populations during establishment of cell cultures may con-
tribute to these apparent discrepancies,
u-PA was found in and around the tumor cells but not in
connection with non-neoplastic cells in the tumor, such as
inflammatory cells. This finding agrees with recent immuno-
histochemical studies by Markus et al . (39) and Camiolo et
al . (60),who demonstrated u-PA inhuman colon and prostate
carcinoma cells, respectively . In view of the fact that u-PA
immunoreactivity in the normal mouse previously was found
to be confined to a certain number of well-defined cell types
(19), the findings in the present study and those reported for
human carcinomas (39, 60) suggest that immunocytochemi-
cal demonstration of u-PA may be valuable for the histopath-
ological diagnosis of cancer.
The preferential localization of u-PA in areas of the tumors
with invasive growth and tissue degradation agrees with the
hypothesis that u-PA in this tumor is involved in these proc-
esses . Invasive growth may be a necessary part of the meta-
static process, and the present results therefore agree with a
recent report by Ossowski and Reich (40), who found that
antibodies that can inhibit the enzyme activity of human u-
PA also inhibited metastases, but not local growth, ofahuman
tumor transplanted onto the chorion-allantoic membrane of
chicken embryos.
As evaluated by immunoblotting, >80% of the activator in
the Lewis lung carcinoma extracts was present in the one-
chain proenzyme form . Taken together with the apparent
extracellular localization of a considerable part of the u-PA
immunoreactivity, this points to the activator being released
from the tumor cells in the pro-enzyme form . This was
previously found to be the case for PA released from virus-
transformed murine cells in culture (3) as well as from cul-
tured human cells of neoplastic origin (2, 4, 5) . Pro-u-PA can
be activated by catalytic amounts of plasmin . However, it
appears likely that as yet unknown factors are involved in
initiating the process leading to plasminogen activation, by
converting extracellular pro-PA to the active form, and that
such factors may be decisive for plasmin-mediated extracel-
lular proteolysis.
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